Immunohistochemistry Market

According to Stratistics MRC, the Global Immunohistochemistry Market is accounted for $2.60 billion in 2022 and is expected to reach $4.24 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Immunohistochemistry is critical for biomarker development. Immunohistochemistry is a microscopy method used to identify antigens and macromolecular cellular components. It requires visualising the presence and localisation of the target protein in various cell types, biological cycles, and even subcellular localization within complex tissues. Recent advancements in IHC include the sensitive detection of numerous proteins in a single sample and the ease of detecting protein-protein interactions. This technique can be used to test drugs and diagnose a variety of ailments.

According to the World Health Organization (WHO) Fact sheet, February 2022, cancer is a leading cause of death worldwide, and accounted for around 10 million deaths in 2020, or nearly one in six deaths.



Market Dynamics:

Driver:

Rising geriatric population

The prevalence of age-related disorders is expected to climb dramatically as the global geriatric population grows rapidly. Geriatric populations are large and growing in other industrialised economies around the world. The chance of developing infections increases proportionally with age. As a result, it is expected that the prevalence of various diseases would increase internationally as the elderly population grows. This is regarded as an important driving force in the Immunohistochemistry (IHC) market for diagnostic applications.

Restraint:

High degree of consolidation

Antibody patent expiration is a major issue for the global market. Some Merck (Germany) and F. Hoffmann-La Roche AG (Switzerland) primary antibodies are about to lose patent protection. Furthermore, market participants must deal with challenges such as growing price pressure from governments around the world and reduced R&D output. To overcome these barriers, prominent market leaders are acquiring smaller and mid-sized firms with unique patented products. This provides a huge financial and distribution platform for these products to enter new global markets.

Opportunity:

New product launches

Key market leaders focusing on technological developments in response to current needs would boost industry development. The market is expected to grow due to the launch of new immunohistochemistry products to address the previously mentioned issues. The top companies are producing cutting-edge goods that are expected to drive market expansion. The introduction of these clinical diagnostic markers might help to advance early-stage drug development for cancer treatment in immuno-oncology. The market would grow quicker throughout the predicted period due to increased R&D.

Threat:

Dearth of skilled professionals

As the prevalence of cancer has increased, so has the demand for pathology services for clinical applications. The majority of examinations conducted on cancer patients are performed using histopathology technologies. However, there is a shortage of trained personnel in these laboratories. A considerable number of histopathologists have reached retirement age, and only a limited number of new histopathologists are being trained. On the other hand, laboratories are under pressure to process an increasing quantity of specimens with restricted personnel.

Covid-19 Impact

The COVID-19 outbreak has had a favourable influence on the immunohistochemistry market, owing to an increase in the prevalence of COVID-19 infections worldwide and an increase in the usage of immunohistochemistry techniques for the detection of COVI-19 infections. For example, immunohistochemistry (IHC) and in situ hybridization (ISH) techniques are employed to detect SARS-CoV-2, according to a July 2020 paper published in Laboratory Investigation. All samples were IHC and ISH positive, whereas all specimens from non-COVID-19 patients were IHC and ISH negative. As a result, the impact of the coronavirus (COVID-19) pandemic has remained positive for the global immunohistochemistry (IHC) market.

The antibody segment is expected to be the largest during the forecast period

The antibody segment is estimated to have a lucrative growth, due to the vital usage of antibodies in disease diagnosis and drug testing. Monoclonal antibodies and antibody-related goods such as Fc-fusion, antibody fragments, and antibody-drug conjugates have surpassed all other product classes in terms of usage rate. The antibodies are used in a variety of applications including pathology, neuropathology, and hematopathology. The increasing usage of research antibodies for drug discovery is another major factor driving the development of the antibodies market.

The diagnosis segment is expected to have the highest CAGR during the forecast period

The diagnosis segment is anticipated to witness the highest CAGR growth during the forecast period. Immunohistochemistry tests can be used to diagnose a variety of chronic disorders, including autoimmune diseases, cancer, infectious diseases, cardiovascular diseases, diabetes mellitus, and nephrological diseases. Furthermore, the growing prevalence of chronic disorders is expected to fuel the diagnostics industry. The majority of infectious diseases and the favourable reimbursement environment for IHC tests are additional factors driving the segment's market share growth.

Region with highest share:

North America is projected to hold the largest market share during the forecast period. The dominance of the North American region can be attributable to the growing use of this immunohistochemistry equipment in diagnostic centres and laboratories. Furthermore, attractive reimbursement regulations in countries like as the United States and Canada encourage the use of automated devices, which helps the growth of the IHC market in the North American region. Additionally, an increase in the number of cancer patients from North American countries is expected to increase the need for these immunohistochemical approaches.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The rapid increase of the Asia-Pacific immunohistochemistry market can be attributed to the economic prosperity of nations such as India, China, South Korea, and Singapore. Furthermore, a big patient pool in countries such as India and China provides a significant number of clinical subjects for IHC R&D tests, leading in revenue growth. Aside from these, the high prevalence of chronic diseases and the rapid ageing of the population are two additional factors driving the growth of the Asia-Pacific Immunohistochemistry Industry.



Key players in the market

Some of the key players profiled in the Immunohistochemistry Market include Agilent Technologies, Inc., Abcam plc., Bio SB, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Merck KGaA, Perkinelmer, Inc., F hoffman La Roche, Eagle Biosciences, Inc., CANDOR Bioscience GmbH, Elabscience, Inc., Thermofischer Scientific Inc and Biogenex Laboratories.

Key Developments:

In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK’s anti-PD1 immunotherapy, JEMPERLI.

In August 2021, Agilent received a CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of oesophageal cancer patients for treatment with KEYTRUDA.

Products Covered:
• Kits
• Antibody
• Equipment
• Reagents

Applications Covered:
• Research Applications
• Diagnosis
• Forensic

End Users Covered:
• Research Institutes and Academic Institutes
• Hospital and Diagnostic Labs
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances